Gerinnungsprobleme in der Intensivmedizin – Update 2019

Ludwig Ney; Michael Spannagl

doi:10.1055/a-0836-6496

Transfusionsmedizin, Table of Contents

Transfusionsmedizin 2019; 9(01): 45-65
DOI: 10.1055/a-0836-6496

CME-Fortbildung

Georg Thieme Verlag KG Stuttgart · New York

Gerinnungsprobleme in der Intensivmedizin – Update 2019

Ludwig Ney

,

Michael Spannagl

Abstract

Störungen des Gerinnungssystems und konsekutive hämorrhagische oder thromboembolische Komplikationen sind in der Intensivmedizin ebenso häufige wie ernsthafte Probleme. Ihre frühzeitige Erkennung, korrekte diagnostische Einordnung und gezielte Behandlung sind entscheidende Faktoren für das Outcome.

Full Text

References

Literatur
1 Maegele M, Schochl H, Cohen MJ. An update on the coagulopathy of trauma. Shock 2014; 41 (Suppl. 01) 21-25
2 Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sang 2005; 89: 123-127
3 Thachil J. Disseminated Intravascular Coagulation: A Practical Approach. Anesthesiology 2016; 125: 230-236
4 Nunez TC, Voskresensky IV, Dossett LA. et al. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)?. J Trauma 2009; 66: 346-352
5 Yucel N, Lefering R, Maegele M. et al. Trauma Associated Severe Hemorrhage (TASH)-Score: probability of mass transfusion as surrogate for life threatening hemorrhage after multiple trauma. J Trauma 2006; 60: 1228-1236
6 McLaughlin DF, Niles SE, Salinas J. et al. A predictive model for massive transfusion in combat casualty patients. J Trauma 2008; 64: S57-S63
7 Hoffman M, Monroe 3rd DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965
8 Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318-1321
9 Subherwal S, Bach RG, Chen AY. et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009; 119: 1873-1882
10 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2016; 37: 2893-2962
11 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100
12 OʼBrien EC, Simon DN, Thomas LE. et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36: 3258-3264
13 Hijazi Z, Oldgren J, Lindback J. et al. The novel biomarker-based ABC (age, biomarkers, clinical history) – bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387: 2302-2311
14 Müller MC, Meijers JC, Vroom MB. et al. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care 2014; 18: R30
15 Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-365
16 Deutsche Gesellschaft für Unfallchirurgie. S3-Leitlinie Polytrauma/Schwerverletzten-Behandlung. Berlin. AWMF 2016. Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/012-019l_S3_Polytrauma_Schwerverletzten-Behandlung_2017-08.pdf Stand: 10.03.2019
17 Spahn DR, Bouillon B, Cerny V. et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013; 17: R76
18 Spinella PC, Perkins JG, Grathwohl KW. et al. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma 2009; 66: S69-S76
19 Holcomb JB, Tilley BC, Baraniuk S. et al. Transfusion of plasma, platelets, and red blood cells in a 1 : 1 : 1 vs. a 1 : 1 : 2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313: 471-482
20 Moore HB, Moore EE, Liras IN. et al. Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients. J Am Coll Surg 2016; 222: 347-355
21 Weber CF, Sanders JO, Friedrich K. et al. Stellenwert der Thrombelastometrie für das Monitoring von Faktor XIII. Prospektive Observationsstudie bei neurochirurgischen Patienten. Hämostaseologie 2011; 31: 111-117
22 Kozek-Langenecker S, Sorensen B, Hess JR. et al. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011; 15: R239
23 Estcourt LJ, Stanworth SJ, Doree C. et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev 2015; (11) CD010983
24 Cannon JW, Khan MA, Raja AS. et al. Damage control resuscitation in patients with severe traumatic hemorrhage: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2017; 82: 605-617
25 Sperry JL, Guyette FX, Brown JB. et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. N Engl J Med 2018; 379: 315-326
26 Shackelford SA, Del Junco DJ, Powell-Dunford N. et al. Association of Prehospital Blood Product Transfusion During Medical Evacuation of Combat Casualties in Afghanistan With Acute and 30-Day Survival. JAMA 2017; 318: 1581-1591
27 McQuilten ZK, French CJ, Nichol A. et al. Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. Transfus Med Rev 2018; 32: 77-88
28 Davenport RA, Brohi K. Coagulopathy in trauma patients: importance of thrombocyte function?. Curr Opin Anaesthesiol 2009; 22: 261-266
29 Besser MW, Ortmann E, Klein AA. Haemostatic management of cardiac surgical haemorrhage. Anaesthesia 2015; 70 (Suppl. 01) 87-95 e29–e31
30 Shakur H, Roberts I, Bautista R. et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32
31 Pollack jr. CV, Reilly PA, van Ryn J. et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med 2017; 377: 431-441
32 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451
33 Connolly SJ, Crowther M, Eikelboom JW. et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019;
34 Committee for Medicinal Products for Human Use (CHMP). Summary of opinion: Ondexxya – Andexanet alfa. London: European Medicines Agency; 2019
35 Majeed A, Agren A, Holmstrom M. et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130: 1706-1712
36 Shaw JR, Siegal DM. Pharmacological reversal of the direct oral anticoagulants – A comprehensive review of the literature. Res Pract Thromb Haemost 2018; 2: 251-265
37 Dager WE, Roberts AJ, Nishijima DK. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. Thromb Res 2019; 173: 71-76
38 Kruger PC, Hirsh J, Bhagirath VC. et al. In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. Thromb Haemost 2018; 118: 1895-1901
39 Desborough MJ, Oakland K, Brierley C. et al. Desmopressin use for minimising perioperative blood transfusion. Cochrane Database Syst Rev 2017; (07) CD001884
40 Raimondi P, Hylek EM, Aronis KN. Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies. Curr Pharm Des 2017; 23: 1406-1423
41 Frontera JA, Lewin 3rd JJ, Rabinstein AA. et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24: 6-46
42 Warren BL, Eid A, Singer P. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286: 1869-1878
43 Gando S, Saitoh D, Ishikura H. et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care 2013; 17: R297
44 Eichacker PQ, Natanson C, Danner RL. Surviving sepsis – practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355: 1640-1642
45 Marti-Carvajal AJ, Sola I, Gluud C. et al. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev 2012; (12) CD004388
46 Yamakawa K, Aihara M, Ogura H. et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13: 508-519
47 Vincent JL, Ramesh MK, Ernest D. et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41: 2069-2079
48 Dickneite G, Herwald H, Korte W. et al. Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. Thromb Haemost 2015; 113: 686-697
49 Wettstein P, Haeberli A, Stutz M. et al. Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 2004; 99: 1564-1569
50 Karkouti K, von Heymann C, Jespersen CM. et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg 2013; 146: 927-939
51 Godje O, Gallmeier U, Schelian M. et al. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006; 54: 26-33
52 Tengborn L, Baudo F, Huth-Kuhne A. et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119: 1529-1537
53 Sakurai Y, Takeda T. Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder. J Immunol Res 2014; 2014: 320674
54 Collins P, Baudo F, Huth-Kuhne A. et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010; 3: 161
55 Kruse-Jarres R, Kempton CL, Baudo F. et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol 2017; 92: 695-705
56 Stemberger M, Möhnle P, Tschöp J. et al. Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy. Haemophilia 2016; 22: e472-e474
57 Charlebois J, Rivard GE, St-Louis J. Management of acquired hemophilia A: Review of current evidence. Transfus Apher Sci 2018; 57: 717-720
58 Collins P, Baudo F, Knoebl P. et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47-55